MUMBAI, India and TOKYO, Japan, April 16, 2026

Piramal Pharma Solutions (PPS) and Ajinomoto Bio-Pharma Services have announced a strategic collaboration aimed at enhancing antibody-drug conjugate (ADC) development and manufacturing capabilities, combining cutting-edge conjugation technology with global GMP manufacturing expertise. The partnership is designed to accelerate the development of highly targeted cancer therapies, leveraging Ajinomoto’s AJICAP™ site-specific conjugation platform and Piramal’s end-to-end contract development and manufacturing (CDMO) capabilities to deliver safe, effective, and scalable ADC solutions across the drug lifecycle.

Strategic Collaboration Strengthens ADC Ecosystem

Under the agreement, both companies will mutually refer customers seeking advanced ADC solutions, creating a seamless ecosystem that integrates technology innovation with commercial-scale manufacturing. Piramal will provide clinical and commercial GMP manufacturing services, while Ajinomoto will contribute its proprietary AJICAP™ technology, which enables precise, site-specific conjugation of antibodies and drug linkers.

A key component of the collaboration includes a planned Material Transfer Agreement (MTA), which will facilitate the transfer of AJICAP™ technology to Piramal, enabling faster technology adoption, scale-up, and production efficiency. This integration is expected to streamline the transition from early-stage development to commercial manufacturing, addressing one of the major bottlenecks in ADC production.

By aligning their capabilities, the companies aim to provide customers with accelerated timelines, reduced complexity, and enhanced product quality, supporting the growing demand for precision oncology therapies.

Advertisement

cGxPJobs Banner

Innovative Technology Enhances Targeted Cancer Therapies

Ajinomoto’s AJICAP™ platform represents a significant advancement in ADC technology, enabling the creation of site-specific conjugates with improved efficacy and reduced toxicity. This approach ensures greater consistency and stability, addressing limitations associated with traditional conjugation methods.

When combined with Piramal’s extensive experience in ADC manufacturing, including over 20 years of expertise and multiple commercial-scale operations, the collaboration creates a powerful platform for delivering next-generation biologics. Piramal’s global network of facilities supports drug discovery, process development, clinical trial supply, and commercial production, ensuring a comprehensive approach to biopharmaceutical manufacturing.

This partnership also supports early-stage pharmaceutical developers, enabling them to access advanced conjugation technologies and scalable manufacturing solutions, ultimately accelerating the delivery of innovative therapies to patients.

Driving Growth in the Global ADC Market

The collaboration comes at a time when the ADC market is experiencing rapid growth, driven by increasing demand for targeted cancer therapies with improved safety profiles. By combining AJICAP™ technology with Piramal’s GMP manufacturing expertise, the partnership is well-positioned to support global pharmaceutical companies and biotech innovators in advancing their pipelines.

Piramal’s position as the world’s first FDA-approved ADC CDMO and its track record of manufacturing multiple commercial ADCs further strengthens the collaboration’s impact. Ongoing expansions in manufacturing capacity are expected to support large-scale production and global distribution, ensuring that innovative therapies reach patients efficiently.

The integration of technology innovation and manufacturing excellence reflects a broader industry trend toward collaborative models in drug development, enabling faster progress and improved outcomes in oncology research and treatment.

The strategic collaboration between Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services marks a significant step forward in advancing ADC development and manufacturing. By combining innovative conjugation technology with global GMP capabilities, the partnership is poised to accelerate the delivery of next-generation targeted therapies, reinforcing the role of biopharmaceutical innovation in transforming cancer treatment.

Source: Piramal Pharma Solutions, Ajinomoto Bio-Pharma Services press release